TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients.
Brief Summary: The investigators plan to compare the effectiveness and cost effectiveness of an inpatient smoking cessation intervention for all smokers hospitalized at two urban public hospitals.


Options:
A: Inclusion Criteria:

* Be receiving care for HIV at one of the participating immunology clinics
* Be 18 years old or older
* Be current (past 7 days) cigarette smoker
* Speak English or Spanish

Exclusion Criteria:

* Are pregnant or nursing
* Have uncontrolled hypertension
* Use other forms of tobacco like cigars or chewing tobacco or are using anything else to help with quitting smoking
* Are allergic to the nicotine patch or have a skin condition like eczema or psoriasis that makes them unable to use the patch
B: Inclusion Criteria:

* Laboratory confirmation of HIV infection
* Montefiore Medical Center Infectious Disease Clinic patient
* Current tobacco user
* Affirmed motivation to quit within the next 6 months
* Have home access to the Internet
* Read above 4th grade level (by REALM)
* Willingness to grant informed consent and undergo randomization

Exclusion Criteria:

* Pregnant or breastfeeding women
* People with contraindications to nicotine replacement therapy
* People currently receiving other tobacco treatment
* Spouses, partners, and/or roommates of current study participants
C: Inclusion Criteria:

* HIV-infection
* current cigarette smoker
* high motivation to quit

Exclusion Criteria:

* Pregnancy
* breastfeeding
D: Inclusion Criteria:

* age ≥ 18 years
* smoked tobacco during the prior 30 days
* have an active phone number
* provide consent in English, Spanish or Mandarin

Exclusion Criteria:

* Patients will be excluded if they use only smokeless tobacco or products such as betel (since there is not yet efficacy data for treating use of these tobacco products in the inpatient setting)
* are pregnant or breastfeeding
* are discharged to an institution (e.g. jail/prison, nursing home, long-term psychiatric facility).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients.
Brief Summary: The investigators plan to compare the effectiveness and cost effectiveness of an inpatient smoking cessation intervention for all smokers hospitalized at two urban public hospitals.


Options:
A: Inclusion Criteria:

* Be receiving care for HIV at one of the participating immunology clinics
* Be 18 years old or older
* Be current (past 7 days) cigarette smoker
* Speak English or Spanish

Exclusion Criteria:

* Are pregnant or nursing
* Have uncontrolled hypertension
* Use other forms of tobacco like cigars or chewing tobacco or are using anything else to help with quitting smoking
* Are allergic to the nicotine patch or have a skin condition like eczema or psoriasis that makes them unable to use the patch
B: Inclusion Criteria:

* Child enrolled in Baltimore City Head Start
* Smoker living in the home with child

Exclusion Criteria:

* No smoker in home with child
* Does not speak English
* Is enrolled in other respiratory research study
C: Inclusion Criteria:

* Adult smoker subjects aged between 35 and 70 years

Exclusion Criteria:

* Previous antecedents of any respiratory disease
* Suffering of any chronic or terminal disorder
* Counterindication to undertake spirometry or that may hinder the performance of the spirometry test
D: Inclusion Criteria:

* age ≥ 18 years
* smoked tobacco during the prior 30 days
* have an active phone number
* provide consent in English, Spanish or Mandarin

Exclusion Criteria:

* Patients will be excluded if they use only smokeless tobacco or products such as betel (since there is not yet efficacy data for treating use of these tobacco products in the inpatient setting)
* are pregnant or breastfeeding
* are discharged to an institution (e.g. jail/prison, nursing home, long-term psychiatric facility).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial
Brief Summary: Diagnosis of tuberculosis (TB) is a challenge because sputum smear, the most rapid and inexpensive test, often fails to detect the disease, in around 20 to 30% of cases. Culture of sputum yields a correct diagnosis in up to 90% of cases, but results are only available in 4 to 8 weeks, depending on the method. A new test (Xpert MTB/Rif) based on a rapid technique, named polymerase chain reaction (PCR), detects TB in less than 2 hours over 95% of cases, in addition to identification of cases resistant to certain drugs used to treat TB. The test is expensive, but several studies have demonstrated its accuracy, and since most steps are automatized, savings can be expected from human resources work. The aims of our study are (1) to evaluate this tool as a substitute test for sputum smears in routine conditions; (2) evaluate if it is cost-effective, meaning that effectiveness of the test may outweigh the extra cost, and (3) evaluate the acceptability of the test among patients and health care workers.


Options:
A: Inclusion Criteria:

1. 2x smear negative or sputum scarce TB suspects
2. Primary care patient (not referred by doctor)
3. Adult patients (\>18 years)
4. Able to provide informed consent

Exclusion Criteria:

1. Not meeting inclusion criteria
2. \<18 years
3. Unable to provide informed consent
B: Inclusion Criteria:

laboratories -and not subjects - will be randomized. All laboratories will start doing smears, when indicated by randomization, they will switch to Xpert MTB/Rif. There are no inclusion or exclusion criteria for the labs. Sputum specimens from non-diagnostic (follow up) patients, second samples for diagnostic tests, insufficient volume/visible blood specimens will be excluded from the Xpert testing.
C: Inclusion Criteria:

1. Community participant willing to complete community-based symptom screening, urine testing and/or undergo TB diagnostic tests at the local TB clinic.
2. Provision of informed consent.
3. HIV-negative adults (older than 18 years) with 1 or more of the following:

   * cough ≥ 2 weeks
   * loss of weight
   * persistent fever ≥ 2 weeks and/or
   * a single recorded temp \> 38°C
   * night sweats
   * generalized fatigue
   * hemoptysis or
   * chest pain
4. Any HIV+ve adult (older than 18 years).

Exclusion Criteria:

1. Inability to provide informed consent (e.g. mentally impaired).
2. Patients self-presenting to the TB clinics.
D: Inclusion Criteria:

* HIV infection
* Fulfills criteria for antiretroviral therapy (CD4 cell count below 350 cells/ml and/or WHO stage IV)
* Residence in study uptake area
* Written informed consent to participation and to tracing in case of defaulting

Exclusion Criteria:

* Ongoing or previous antiretroviral therapy
* Treatment for active tuberculosis for more than two weeks

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy
Brief Summary: This project aims to: 1) evaluate the long-term effectiveness of telemedicine to detect diabetic retinopathy when compared to traditional surveillance methods, 2) identify the health belief factors related to adherence with annual diabetic eye exams, and 3) determine the cost-effectiveness of the telemedicine system from the perspective of the community clinic, the third-party payer, and the individual patient.


Options:
A: Inclusion Criteria:

* Diagnosis of diabetes mellitus (based on fasting glucose, HbA1c, and problem list)
* At least 18 years old
* At least one face-to-face visit with Harvard Vanguard primary care clinician in the last 2 years

Exclusion Criteria:

* Any patient not categorized as either White or Black based on race identifier in the electronic medical record
B: Inclusion Criteria: diagnosis of type 2 diabetes, age 21 years and above, resident of American Samoa receiving primary care at Tafuna Family Health Center -

Exclusion Criteria: pregnancy, receiving kidney dialysis

-
C: Inclusion Criteria:

* diabetic, at least 18 years old, patient at a participating health clinic
D: Inclusion Criteria:

Self-Identify as having diabetes, be 55 years of age or older, Latino/a and have a hemoglobing A1c of 8% or greater.

Exclusion Criteria:

Non diabetic, under 55, non Latino/a, a hemoglobin A1c of less than 8%.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy
Brief Summary: This project aims to: 1) evaluate the long-term effectiveness of telemedicine to detect diabetic retinopathy when compared to traditional surveillance methods, 2) identify the health belief factors related to adherence with annual diabetic eye exams, and 3) determine the cost-effectiveness of the telemedicine system from the perspective of the community clinic, the third-party payer, and the individual patient.


Options:
A: Inclusion Criteria:

* ages 18-79
* diagnoses of diabetes, hypertension, and/or congestive heart failure

Exclusion Criteria:

* pregnant
* unable to understand randomization process
B: Inclusion Criteria:

* diabetic, at least 18 years old, patient at a participating health clinic
C: Inclusion Criteria:

* Prevalent Type 2-diabetes as confirmed by Primary Care Physician.
* Patient alive throughout the intervention period.
* GP actively working throughout the intervention period (not retired).

Exclusion criteria:

* death during intervention
* moved out of geographic area during intervention
* GP retired during intervention
D: Inclusion Criteria:

* Alive on 1 July 2009 with prevalent diabetes

Exclusion Criteria:

* Age \<= 39
* Residing in long-term care

Secondary Analysis:

* Analysis will be repeated using all people alive on 1 July 2009 without prevalent diabetes using the same exclusion criteria, to determine the spill-over effect of the Intervention on physicians' other patients.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy
Brief Summary: This project aims to: 1) evaluate the long-term effectiveness of telemedicine to detect diabetic retinopathy when compared to traditional surveillance methods, 2) identify the health belief factors related to adherence with annual diabetic eye exams, and 3) determine the cost-effectiveness of the telemedicine system from the perspective of the community clinic, the third-party payer, and the individual patient.


Options:
A: Inclusion Criteria:

* diabetic, at least 18 years old, patient at a participating health clinic
B: Inclusion Criteria:

* Be age 18 years and older
* Have physician-diagnosed plaque psoriasis
* Have access to internet and a digital camera or a mobile phone with camera features
* Have a primary care provider or the ability to establish primary care

Exclusion Criteria:

-
C: Inclusion Criteria:

CHWs in districts with ICCM implementation

Exclusion Criteria:

CHWs in districts without ICCM implementation
D: Inclusion Criteria: those who

* are aged more than 18 years old;
* have a history of stroke (including ischemic and hemorrhagic stroke) diagnosed at county hospital or higher-level facilities, and currently in a clinically stable condition and not receiving acute stroke treatment;
* will live in this village for at least nine months during the next 12 months;
* have a basic communication ability (i.e. can understand simple instructions);
* give participant informed consent and are willing to participate in the study.

Exclusion Criteria: those who

* are unable to get out of bed without maximum assistance;
* have serious life-threatening disease such as cancers;
* who have an expected life span of less than 6 months.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Improving Urinary Continence and Quality of Life in Prostate Cancer Patients
Brief Summary: This intervention program combines biofeedback PFME with a telephone or support group intervention to treat persistent urinary incontinence (UI). The study's primary aims are to improve continence, quality of life, and mood through enhancing adherence to PFME and self-management of incontinence symptoms. The secondary aims are to examine the physiological effects and cost effectiveness of the proposed interventions.


Options:
A: Inclusion Criteria:

* Volunteers between 50 and 75 years old;
* Submitted to radical prostatectomy;
* With complaints of urinary incontinence;
* That completed one month of surgery;

Exclusion Criteria:

* History of incontinence;
* Transurethral resection of the prostate;
* Diagnosis of neurological or cognitive impairment;
* Subjects who were unable to attend treatment sessions, due to distance or physical limitations.
B: Inclusion Criteria:

* Prostate cancer patients who underwent robotic radical prostatectomy
* Neurovascular saving at least one side
* Bladder neck reconstruction at prostatectomy
* Posterior reconstruction at prostatectomy
* Patients who have post-prostatectomy incontinence after Foley catheter removal

Exclusion Criteria:

* Patients who have not post-prostatectomy incontinence after Foley catheter removal
* Neurological deficits
* Anatomic deformities of pelvic bone
* Pelvic irradiation history
* History of other major urological procedures
* Complications influencing urinary incontinence
C: Inclusion Criteria:

* Men who have undergone a radical prostatectomy at least 1 year prior to enrollment
* Incontinence induced by the surgery (at least 8 g/24 hours)
* Capable of understanding study information and following treatment

Exclusion Criteria:

* Incontinence before radical prostatectomy
* Treatment with anticholinergic medications
* Radiation or hormone treatment
* Previous surgical treatment of incontinence
* Acute illness (including infection, trauma and haematuria)
* Faecal incontinence
* Known neurological disease
* Known Bladder pathology on cystoscopy
D: Inclusion Criteria:

1. Have been diagnosed with early stage (I-III) prostate cancer.
2. Have completed cancer treatments six months prior.
3. Presence of incontinence symptoms

Exclusion Criteria:

1. Receiving hormonal treatment.
2. Urinary tract infection or urinary retention.
3. Cognitive impairment.
4. Having an implant

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of lower doses of primaquine compared to the dose recommended by the WHO for reducing P. falciparum gametocytes in the infected human host to prevent transmission of falciparum malaria to the anopheles mosquito vector.


Options:
A: Inclusion Criteria:

* infection with P.falciparum detected by PCR

Exclusion Criteria:

* pregnancy
* severe anaemia
* fever or other signs of illness
* history of allergy to sulfa drugs
* presence of other species of Plasmodium detected by microscopy
B: Inclusion Criteria:

* permanent resident of the research area
* age \>1 years

Exclusion Criteria:

* severe anemia
* pregnancy
C: Inclusion Criteria:

* age ≥ 4 years old
* parasite count ≥ 1,000 asexual parasites/µL
* normal glucose-6-phosphate dehydrogenase enzyme level based on qualitative test (Trinity Biotech® no 203, USA)
* hemoglobin level ≥ 8 gr/dL as measured by Hemoque® apparatus;
* have the ability to return for 42-day-follow up and
* willingness to sign the informed-consent form.

Exclusion Criteria:

* are infected with other r plasmodium species
* have only gametocytes of P. falciparum;
* are pregnant - measured by positive result on HCG urine test and/or breastfeeding women
* present signs of pitting edema on both legs as a sign of malnutrition
* have complicated or severe malaria, other chronic diseases or history of drug allergies.
D: Inclusion Criteria:

* Age \>/= 1 year and \</= 10 years
* Weight over 10kg
* Fever \>38 degrees C (tympanic) or history of fever in the last 24 hours
* P. falciparum parasitaemia \<500 000/µl
* Normal G6PD enzyme function

Exclusion Criteria:

* Enrolled in another study
* Evidence of severe illness/ danger signs
* Known allergy to study medications
* Haemoglobin \< 8g/dL)
* Started menstruation
* Pregnancy or breastfeeding
* Primaquine taken within the last 4 weeks
* Blood transfusion within the last 90 days
* Non-falciparum malaria co-infection

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects on Cytokines, Immunoglobulins, Antibodies, Sphingomyelinase and PAF Hydrolysis Capacity in the Maternal Milk After Probiotic VSL#3 Administration in the Last Four Weeks of Gestation and First Month of Lactation
Brief Summary: The newborn immune system is influenced by maternal immunity through both placenta and breastfeeding.

There exists a close interaction between the mother and the baby during gestation and lactation. Maternal milk contains a number of factors that protect the newborn against infections including 1) cytokines and their receptors which are also thought to play a role in the protection against allergies; 2) oligosaccharides with low molecular weight and 3) probiotic bacteria that contribute to the development of the newborn immune system.

Probiotics have a potent immunogenic activity as well as an immunoprotective potential in maternal milk after administration of probiotics during pregnancy and breastfeeding. In addition probiotics are supposed to play a role in the increased production of sphingomyelinase.


Options:
A: Inclusion Criteria:

-Asymptomatic pregnant women with no indication of elective preterm delivery, before the 20th week of pregnancy

Exclusion Criteria:

* major malformations in present pregnancy
* cervical cerclage
* symptomatic vaginosis
* insulin dependent diabetes
* arterial hypertension
* Multiple gestation
* Antibiotic therapy in present pregnancy
* Syphilis or gonorrhea in present pregnancy
* asthma requiring chronic or intermittent therapy
* corticotherapy(recent or chronic)
* perinatal hemolytic disease
* Systemic Erit. Lupus
B: Inclusion Criteria:

* BMI ≥ 30 and ≤35 kg/m2- calculated from pre-pregnancy weight
* Primiparous singleton pregnancy
* Able to read and speak Danish
* Normal ultrasound scan of the fetus at gestational age 12-14
* Oral glucose tolerance test at gestational age 14-20

Exclusion Criteria:

* Pregnancy at \> 20 weeks gestation at recruitment
* Pre-gestational diabetes or other serious diseases
* Multiple pregnancy
* Previous bariatric surgery
* Ingestion of probiotics \< 1 month before the inclusion or ingestion of other kinds of probiotics than the study probiotics
C: Inclusion Criteria:

* Pregnant women from families with at least one family member having an allergic disease

Exclusion Criteria:

* Women presenting severe immunological or other chronic diseases (rheumatoid arthritis, diabetes, inflammatory bowel disease, thyroid diseases, malignancies etc.)
* Women who cannot be expected to comply with treatment
* Women currently participating or having participated in other clinical trial during the last 2 months prior to the beginning of the intervention.
D: Inclusion Criteria:

* over 18 years old
* able to give informed consent

Exclusion Criteria:

* twin pregnancies, pregnancy diseases (threat of miscarriage, maternal chronic conditions)

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Technology Enhanced Delivery of Treatment for Early Conduct Problems
Brief Summary: This study aimed to examine if technology could enhance the treatment engagement and outcomes of low income parents of 3 to 8 children with externalizing problems.


Options:
A: Inclusion Criteria:

* Pregnant women prior to the 25th week of gestation
* no previous live births
* one of the following sociodemographic risk characteristics:

  * young age (\< 19 years at registration);
  * unmarried
  * low socioeconomic status (Medicaid status or no private insurance)
B: Inclusion Criteria:

* Child is 4 years old at time of recruitment
* Parent/guardian has access to a computer and the internet
* Parent/guardian is comfortable reading at a Grade 5 level
* Child meets screening criteria (SDQ score of 4 or more with some problems per impact score)

  * Child has had behavioural challenges for the last 6 months
  * Parent has access to phone in home
  * Parent speaks/writes Finnish

Exclusion Criteria:

* - Has received or is receiving behavioral treatment (parent training) before
* Diagnosis of:

  * Autism or a Pervasive development disorder (PDD)
  * Down's syndrome
  * Fetal Alcohol Syndrome
  * Mental retardation
  * Genetic diagnosis that will lead to mental retardation
  * Major mental health disorder (e.g., depression, psychosis)
* Child is not speaking using a sentence
* Child is deaf or blind
C: Inclusion Criteria:

* Child aged 3 to 7 years
* has clinically significant disruptive behaviors
* low-income family

Exclusion Criteria:

* Caregiver has current mood, substance use, and/or psychotic disorder
* Child has current pervasive developmental and/or psychotic disorder
* Family has current allegation and/or past substantiation with child protective services
D: Inclusion Criteria:

* Lower income
* caregiver/parent is legal guardian
* 3 to 8 year old child
* child meets criteria for externalizing disorder or significant externalizing symptoms

Exclusion Criteria:

* Prior report of child abuse or neglect
* current substance abuse/dependence
* legal guardian reading level less than 8th grade
* child has developmental disability that precludes caregiver utilizing the skills

Answer: D